An interventional study of Filtered Air (FA) and Wood Smoke (WS) in Healthy Individuals and Allergic Rhinitis, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Rhinitis, Allergic with a site in Canada — 3 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · Canada.
Among the 49 studies in Rhinitis, Allergic with a site in Canada, this one is the 26th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 46th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →3 of the 49 studies in Rhinitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:
Dr. Anne Ellis · Sites in Canada
Ages 18–70 · Healthy volunteers
Lakehead University · Sites in Canada
Ages 19–39 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 19 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 6 · Phase 4 7
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 60 across the 45 interventional studies, 58 across the 4 observational. Of the 40 that completed or were terminated, 19 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 49 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,340 studies on the registry; 260 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 3 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
2 of the studies in Rhinitis, Allergic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06189742Dr. Anne EllisTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) | 2026-12 |
| NCT06749093University of British ColumbiaHealth Effects of Wood Smoke and Traffic-Related Air Pollution Exposures: a Necessary Comparison | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Rhinitis, Allergic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Accumulating evidence demonstrates that breathing air pollutants leads to devastating increases in sickness and death worldwide over time. However, there is little data comparing the effects of different types of air pollution on health. In Canada, traffic-related air pollution and wood smoke (wildfires and wood burning for heating) are very common air pollutants. This study aims to safely complete a controlled human exposure study to test how these air pollution types acutely affect health.
Healthy adult participants (total 48; 24 of each biological sex assigned at birth) will breathe filtered air (control), wood smoke (WS), diesel exhaust (DE), and DE plus WS (DEWS) each for 2 hours, with 4 weeks between each exposure (washout). Before and after each exposure, participants will answer questions, perform breathing tests, and give blood samples. At 24 hours after each exposure, participants will undergo a bronchoscopy to collect samples from their lungs.
The study will look at what (if any) are the differences between breathing in fresh air (filtered air - FA) or polluted air containing either wood smoke (WS), diesel exhaust (DE) or diesel exhaust plus wood smoke (DEWS). The research team will use wood smoke generated from pine wood, since it is one of the most common types of wood found in Western Canadian forests where forest fires occur.
The investigators will evaluate multiple endpoints as detailed in the Outcome Measures section. For each applicable endpoint, the investigators will evaluate stratified analyses and effect modification by biological sex, participant age, gene score, and microbiomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be exposed to 2 hours of high-efficiency particulate air (HEPA) filtered air (FA).
Other: Filtered Air (FA)
Participants will be exposed to 2 hours of controlled wood smoke (WS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Other: Wood Smoke (WS)
Participants will be exposed to 2 hours of controlled diesel exhaust (DE) as a model of traffic-related air pollution (TRAP) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Other: Diesel Exhaust (DE)
Participants will be exposed to 2 hours of combined controlled diesel exhaust (DE) and wood smoke (DEWS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Other: Diesel Exhaust and Wood Smoke (DEWS)
Exposure to HEPA filtered air, as a control
Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Also known as: Traffic-Related Air Pollution
Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Also known as: Air Pollution
Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on inflammatory cells in the lungs.
Differentially count lung cells.
Time frame: Comparison of the different arms (over the span of ~5 months).
Within-individual change in lung transcriptomic biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.
Within-individual change in lung biomarkers of inflammation (serum amyloid A (SAA), c-reactive protein (CRP), chemokine ligand 18 (CCL18), and fibrinogen) in RNA.
Time frame: Through study completion, anticipated ~5 months.
Within-individual change in lung protein biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.
Within-individual change in lung biomarkers of inflammation (serum amyloid A (SAA), c-reactive protein (CRP), chemokine ligand 18 (CCL18), and fibrinogen) in protein.
Time frame: Through study completion, anticipated ~5 months.
Within-individual change in circulating transcriptomic biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.
Within-individual change in circulating biomarkers of inflammation (CX3CL1, CCL23, CXCL8, SAA, MMP9, MMP12, APOB, APOM, SOD1, NQO1, HMOX1, CAT, CYP1B1, CYP1A2, NFE2L2 and AHRR) in RNA.
Time frame: Through study completion, anticipated ~5 months.
Within-individual change in circulating protein biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.
Within-individual change in circulating protein biomarkers of inflammation (CX3CL1, CCL23, CXCL8, SAA, MMP9, MMP12, APOB, APOM, SOD1, NQO1, HMOX1, CAT, CYP1B1, CYP1A2, NFE2L2 and AHRR).
Time frame: Through study completion, anticipated ~5 months.
Within-individual change in airway resistance following exposures to woodsmoke and/or diesel exhaust.
Within-individual change in airway resistance, as measured by impulse oscillometry (resonant frequency (Fres) and peripheral airway resistance (R5-R20)) across exposures to woodsmoke and/or diesel exhaust relative to filtered air.
Time frame: Through study completion, anticipated ~5 months.
Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on inflammatory cells in the nose.
Differentially count nasal cells.
Time frame: Comparison of the different arms (over the span of ~5 months).
Within-individual changes in exhaled nitric oxide following woodsmoke (WS) and/or diesel exhaust (DE) exposures.
Measurement of fractional exhaled nitric oxide (FeNO) in parts per billion (ppb).
Time frame: Comparison of the different arms (over the span of ~5 months).
Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on symptoms, stress and perceptions.
Visual analog score (0-100) questionnaire will be completed, with a higher score indicating a worse outcome.
Time frame: Comparison of the different arms (over the span of ~5 months).
Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on lung function.
Lung function as evaluated by spirometry (e.g. FEV1).
Time frame: Comparison of the different arms (over the span of ~5 months).
Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on nasal resistance.
Measurement of peak nasal inspiratory flow (PNIF).
Time frame: Comparison of the different arms (over the span of ~5 months).
Plan to share: Yes — Participant data that underlie the results reported in accepted articles for publications, after deidentification (text, tables, figures, and appendices).
Time frame: Immediately following publication. No end date.
Access criteria: Researchers who provide a methodologically sound proposal to the PI to complement the approved study aims.
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.
Of 66 non-industry interventional studies with no phase under Rhinitis, Allergic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 17 months is above that.
Counting every sponsor, half of 87 studies reached it within 11 months; a quarter within 4 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →